In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alvotech Reels In Abdi Ibrahim For Access To Turkey

Executive Summary

In a move to take its pipeline of biosimilar monoclonal antibodies global, Alvotech has struck a deal with Abdi Ibrahim that will give it localization advantages in Turkey.

You may also be interested in...



Alvotech Strikes $45m Deal With Yas

Alvotech has struck an investment deal worth $45m with Yas Holding that will give Yas a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.

Alvotech And Fuji Stretch Alliance To Ustekinumab In Japan

Alvotech and Fuji Pharma have extended their alliance to cover exclusive development and supply of biosimilar ustekinumab in Japan. 

Alvotech To Develop Biosimilar Assets With US$300m Financing Deal

Alvotech will further develop its biosimilar assets through a US$300 million financing deal that will also enable the firm to “fuel continued growth” and be used for refinancing existing debt.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel